Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 43Rectal Neoplasms 12Colonic Neoplasms 12Neoplasm Metastasis 6Stomach Neoplasms 5Pancreatic Neoplasms 5Gallbladder Neoplasms 3Colorectal Cancer Metastatic 3Cholangiocarcinoma 3Neutropenia 2Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2mCRC 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Recurrence 1Pretreated Metastatic Colorectal Cancer 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Carcinoma 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1High-grade Extra Pulmonary Neuroendocrine Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
23 enrolled 12 charts
Gastrointestinal

Stomach Neoplasms

NCT07212933 2025-10-08

RAK in GC

Chinese PLA General Hospital

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

Phase 1/2 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05029102 2024-02-12

TAS-102 and Anlotinib in ≥3 Lines mGC

Zhejiang University

Phase 2 Unknown
45 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06102785 2023-10-26

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Tianjin Medical University Cancer Institute and Hospital

Recruiting
30 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡